Australian pharmaceutical company AUPharma has sued the international arm of Purdue, alleging it was wrongly granted patent extensions for several oxycodone products marketed as Targin.
A judge has dismissed a class action brought against animal health giant Zoetis over alleged side effects resulting from its Hendra virus horse vaccine, finding there were “too many uncertainties” in the applicant’s evidence.
The operator of the Royal Perth Hospital has brought legal action against Griffith Hack alleging the law firm contributed to the “dishonest and fraudulent design” of a leading researcher to transfer the intellectual property rights to a stem cell manufacturing method developed inhouse.
Medibank is facing another class action investigation over a massive data breach that left the personal information of almost 10 million customers exposed, just days after criminals began publishing sensitive customer health data.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
A judge has ordered Smile Direct Club and its Australian unit to pay a $3.5 million penalty and reimburse customers for misleading them into believing they would be reimbursed by their insurers for the dental care company’s costly teeth straighteners.
A class action investigation over the data breach that exposed the personal information of almost 10 million Medibank customers is underway, with two law firms teaming up to probe whether the private health insurer is liable for damages.
Medibank will not pay a ransom to a criminal who stole the data of 9.7 million customers, saying it would encourage extortion.
A top orthopaedic surgeon and former NSW Australian of the year has sued Channel Nine and Fairfax for defamation over a recent 60 Minutes episode and articles that appeared in The Age and the Sydney Morning Herald.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…